The global Cannabis Pharmaceuticals Market size is projected to reach USD 5.8 billion by 2027, expanding at a CAGR of 76.8% over the forecast period, according to a new report by Grand View Research, Inc. Rise in the number of clinical trials for these drugs due to its therapeutic properties, growing awareness of the medical benefits of plant-derived cannabidiol products are some of the factors driving the demand over the forecast period. However, the presence of stringent regulations on cannabidiol-infused products in various countries is restricting demand for these products.
In 2019, Sativex is the leading brand in the global market with a revenue share of 83.0%. The surge in clinical trials for numerous medical conditions and the growing number of countries legalizing cannabis for medical purposes are the major factors responsible for its large share. On the other hand, Epidiolex is anticipated to be the fastest-growing brand over the forecast period. Growing research for plant-based cannabinoids for other rare conditions is expected to drive the growth of this segment over the forecast period.
The European region is expected to dominate the market in 2019, owing to growing medical marijuana users in the region coupled with the rising awareness about cannabidiol infused products. On the other hand, the Asia Pacific region is expected to grow at the fastest…
Original Author Link click here to read complete story..